Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is projected to have a market value of $1.05B, translating to a 12-month price objective of $11 per share. This is based on a DCF model using a 10% discount rate, a 1.0% terminal growth rate, and an effective tax rate of 29.84%, with a 60% probability of approval for vispa-cel (CB-010) and a 35% probability of approval for CB-011. However, risks to this valuation include negative clinical results, delays in advancing candidates, failure to achieve favorable clinical results with other pipeline candidates, regulatory approval challenges, and competition.

Bears say

Caribou Biosciences is facing significant risks due to negative clinical results and delays in advancing their lead assets, CB-010 and CB-011, into registration programs. These risks are compounded by potential failures to achieve favorable clinical results with other pipeline candidates and the potential inability to obtain timely regulatory approvals. The company's 11% discount rate and 1.0% terminal growth rate in the DCF-based valuation suggests a lack of confidence in the company's potential for future growth.

Caribou Biosciences (CRBU) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.